Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GALT $11.61 1.3300 +12.94%
PVCT $2.32 0.2100 +9.95%
SRNE $10.55 0.9000 +9.33%
AMBI $6.94 0.5300 +8.27%
CYTR $3.23 0.2300 +7.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

INO $2.52 -0.1500 -5.62%
THLD $3.83 -0.1900 -4.73%
INFI $10.15 -0.4500 -4.25%
NYMX $5.04 -0.2199 -4.18%
KPTI $31.09 -1.3100 -4.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

Statement from ASH President Linda J. Burns, MD, on Release of Medicare Physician Payment Data

(ASH) Apr 9, 2014 - Today the Centers for Medicare & Medicaid Services released a large and complex set of data about the number and type of health-care services that individual physicians and certain other health-care professionals delivered in 2012, and the amount Medicare paid them for those services.
read press release 

Fox Chase Study Examines Protein Expression Biomarkers in HPV Negative Squamous-Cell Carcinomas of the Head and Neck

(Fox Chase) Apr 8, 2014 - A quartet of proteins that play critical roles in cell replication, cell death, and DNA repair could lead to better targets for therapy against treatment-resistant head-and-neck squamous cell cancers.
read press release 

Dartmouth Researchers Identify Potential Therapeutic Target for Deadly Brain Cancer

(Dartmouth-Hitchcock Norris) Apr 8, 2014 - Dartmouth research presented at the AACR Annual Meeting 2014 identifies a potential characteristic for predicting outcome in a deadly form of brain cancer known as glioblastoma multiforme.
read press release 

Deep, Integrated Genomic Analysis Re-classifies Lower-grade Brain Tumors

(MD Anderson) Apr 8, 2014 - Three molecularly defined clusters could alter practice; one closely resembles deadly glioblastoma.
read press release 

Nektar Reports Positive Preclinical Data for Two Oncology Programs at 2014 AACR

(MarketWatch) Apr 9, 2014 - Nektar Therapeutics today announced that preclinical data for NKTR-102 and NKTR-214 were presented at the 2014 AACR Annual Meeting.
read article 

Study Highlights New Drug, Molecular Insight Into Triple Negative Breast Cancers

(UCCC/In the Lab blog) Apr 8, 2014 - A University of Colorado Cancer Center study presented today at the AACR Annual Meeting 2014 showcased a new drug active against triple-negative breast cancer.
read article 

Studies Reveal More Clues on How Pregnancy Protects Against Breast Cancer

(Fox Chase) Apr 7, 2014 - Scientists at Fox Chase Cancer Center have unearthed new clues about how pregnancy reduces women's risk of developing breast cancer.
read press release 

Dosage and Timing May Improve Effectiveness of PI3K-inhibitors in Breast Cancer

(Dartmouth-Hitchcock Norris) Apr 9, 2014 - A Dartmouth study suggests that manipulation of drug dosage and schedules may improve anti-tumor effects of PI3K-inhibitors to target breast cancer tumors.
read press release 

Fox Chase Study Identifies the Process in which Heat Shock Protein 90 Contributes to Metastases in Ovarian Cancer

(Fox Chase) Apr 8, 2014 - By incapacitating the activities of a protein that guides other proteins to fold into stable shapes, Fox Chase Cancer Center researchers shut off the spigot for two proteases that help ovarian cancer cells chew their way out of the tissue they grow in and dig in at new locations.
read press release 

Irregular Menstruation May Predict Increased Risk of Death From Ovarian Cancer

(AACR) Apr 9, 2014 - Women with irregular menstrual cycles had a twofold increased risk of death from ovarian cancer, according to a large, prospective study presented at the AACR Annual Meeting 2014.
read press release 

Gold Nanorods Attach to, Kill Bladder Cancer Cells

(UCCC/In the Lab blog) Apr 7, 2014 - A major strategy of modern cancer research is to discover a difference between cancerous and healthy cells and then to specifically target this difference to kill cancer cells without harming healthy tissue.
read article 

Higher Coffee Intake May Reduce Liver Cancer Risk

(AACR) Apr 9, 2014 - The more cups of coffee a person drank, the lower the risk for developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to results presented at the AACR Annual Meeting 2014.
read press release 

Milk Thistle Extract, Silibinin, Reduces Self-Renewal of Colorectal Cancer Stem Cells

(UCCC/In the Lab blog) Apr 7, 2014 - Colorectal cancer stem cells thrive in conditions of inflammation.
read article 

Prediagnosis Obesity Predicts Poor Outcome for Colorectal Cancer Patients, Even Those With a Tumor Marker Linked to Better Outcomes

(AACR) Apr 9, 2014 - High body mass index (BMI), an indicator of obesity, before a colorectal cancer diagnosis was associated with increased risk of death after diagnosis, even when tumors harbored the microsatellite instability (MSI) marker normally associated with better prognosis, according to results of a large prospective study at the AACR Annual Meeting 2014.
read press release 

Unexpected Results in Cancer Drug Trial

(University of Southampton [UK]) Apr 8, 2014 - Research from the University of Southampton has shown a drug, used in combination with chemotherapy to treat advanced colorectal cancer, is not effective in some settings, and indeed may result in more rapid cancer progression.
read press release 

Chemo Might Give Certain Lung Cancer Patients an Edge

(U.S. News & World Report/HealthDay News) Apr 8, 2014 - Cancer specialists have been unsure about how best to treat certain patients with an advanced form of lung cancer.
read article 

FDA Halts Halozyme's Pancreatic Cancer Study

(Reuters) Apr 9, 2014 - Halozyme Therapeutics Inc said the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial.
read article 

Small Slice of Doctors Account for Big Chunk of Medicare Costs

(Wall Street Journal) Apr 9, 2014 - A tiny sliver of doctors and other medical providers accounted for an outsize portion of Medicare's 2012 costs, according to an analysis of federal data that lays out details of physicians' billings.
read article (paid subscription required) 

Cancer-Fighter Juno Therapeutics Hits The Pause Button On Trial After Patient Deaths

(Forbes) Apr 8, 2014 - Over the weekend at the annual meeting of the American Association for Cancer Research, two of Juno’s founders revealed that two patient deaths had led them to stop giving new patients a new cell therapy until changes could be made to their clinical trial.
read article 

Zogenix Wins U.S. Approval for Pure Hydrocodone Pain Pill

(Bloomberg) Apr 8, 2014 - Zogenix Inc. won approval to sell the first painkiller made of pure hydrocodone as U.S. regulators recommended restrictions on popular combination treatments with the drug. The decision helped Zogenix shares climb the most in eight months.
read article 

Alkermes to Seek Schizophrenia Drug Approval After Trial Success

(Reuters) Apr 8, 2014 - Alkermes Plc said it planned to seek U.S. marketing approval for its experimental drug to treat the symptoms of schizophrenia after it succeeded in a late-stage study, sending the company's shares up as much as 11 percent.
read article 

Gilead Aims to License Hepatitis C Drug to 3-4 Indian Firms

(Reuters) Apr 8, 2014 - Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.
read article 

Express Scripts Raises Pressure on Gilead to Cut Drug Price

(Washington Post/Bloomberg) Apr 8, 2014 - Express Scripts Holding Co., a pharmacy benefit manager that handles more than 1 billion prescriptions a year in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. to cut the $84,000 price of its new hepatitis C pill Sovaldi.
read article (free registration required) 

Gilead Hepatitis C Treatment Designated for FDA Priority Review

(NASDAQ/Dow Jones Business News) Apr 7, 2014 - Gilead Sciences Inc. on Monday said the Food and Drug Administration has placed the company's new drug application for a hepatitis C treatment under priority review.
read article 

Daiichi Sankyo to Sell Troubled Ranbaxy

(Wall Street Journal) Apr 7, 2014 - Daiichi Sankyo, unable to remedy chronic regulatory problems at Indian generics maker Ranbaxy Laboratories, is selling its controlling stake in the company amid heightened U.S. scrutiny of safety lapses there.
read article (paid subscription required)